KaydedilenlerDerginizi ekleyin

Dergiler / Marmara Medical Journal / 2026 / Volume: 21 Issue: 1

75 YAŞ VE ÜZERİ LOKAL İLERİ VE METASTATİK KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİNDE PRİMER VE PALYATİF TEDAVİ OLARAK RADYOTERAPİ UYGULAMASI: 45 VAKANIN DEĞERLENDİRİLMESİ VE LİTERATÜR İNCELEMESİ

-

Görkem Aksu
Merdan Fayda
Mert Saynak
Esra Kaytan Saglamer
Ethem Nezih Oral
Ahmet Kizir
Ahmet Karadeniz
Sayfa
—
Yayın Tarihi
2015-06-23
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Evre IIIB tanılı hastaların 14 tanesine (41%) küratif Radyoterapi (RT), 18 hastaya (52%) palyatif RT uygulanırken, 2 hasta (5%) sadece kemoterapi (KT) aldı.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Amaç: Lokal ileri veya metastatik KHDAK tanılı hastalarda prognostik faktörler ve tedavi sonuçlarının değerlendirilmesi Hastalar ve Yöntem: Yetmiş beş yaş ve üzeri toplam 45 KHDAK tanılı hasta değerlendirildi.
📊
Temel Bulgular & Veri:Medyan yaş 78 idi (75-93).
💡
Sonuç & Katkı:Evre IIIB tanılı hastaların 14 tanesine (41%) küratif Radyoterapi (RT), 18 hastaya (52%) palyatif RT uygulanırken, 2 hasta (5%) sadece kemoterapi (KT) aldı.
🔬Tür:Article
📍Kapsam:11 hasta
⚙️Değişkenler:Yaşlı · Akciğer kanseri · Prognostik faktörler

Özet

Amaç: Lokal ileri veya metastatik KHDAK tanılı hastalarda prognostik faktörler ve tedavi sonuçlarının değerlendirilmesi Hastalar ve Yöntem: Yetmiş beş yaş ve üzeri toplam 45 KHDAK tanılı hasta değerlendirildi. Medyan yaş 78 idi (75-93). Otuz dört hasta Evre IIIB (75%), 11 hasta (25%) ise Evre IV olarak evrelendirildi. Evre IIIB tanılı hastaların 14 tanesine (41%) küratif Radyoterapi (RT), 18 hastaya (52%) palyatif RT uygulanırken, 2 hasta (5%) sadece kemoterapi (KT) aldı.

Abstract

-

🔖

Bu Makaleye Atıf Yap

Aksu, G., Fayda, M., Saynak, M., Saglamer, E. K., Oral, E. N., Kizir, A., Karadeniz, A. (2015). 75 YAŞ VE ÜZERİ LOKAL İLERİ VE METASTATİK KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİNDE PRİMER VE PALYATİF TEDAVİ OLARAK RADYOTERAPİ UYGULAMASI: 45 VAKANIN DEĞERLENDİRİLMESİ VE LİTERATÜR İNCELEMESİ. Marmara Medical Journal, Volume: 21 Issue: 1. https://ajindex.com/articles/1287082

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (113)

  1. Lonardi F, Coeli M, Pavanato G, Adami F, Gioga G,
  2. Campostrini F. Radiotherapy for non-small cell lung
  3. cancer in patients aged 75 and over, safety, effectiveness
  4. and possible impact on survival. Lung Cancer 2000; 28:
  5. Tombolini V, Bonanni A, Donato V, et al. Radiotherapy
  6. alone in elderly patients with medically inoperable stage
  7. IIIA and IIIB non-small cell lung cancer. Anticancer Res; 20,:4829-4833.
  8. Rengan R, Rosenzweig, KE, Venkatraman E, et al.
  9. Improved local control with higher doses of radiation in
  10. large-volume stage III non-small-cell lung cancer. Int J
  11. Radiat Oncol Biol Phys 2004;60:741-747.
  12. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Longterm
  13. survivors in metastatic non-small cell lung cancer:
  14. an Eastern Cooperative Oncology Group Study. J Clin
  15. Oncol 1986;4:702–709.
  16. Albain KS, Crowley JJ, LeBlanc M, Livingston RB.
  17. Survival determinants in extensive-stage non-small cell
  18. lung cancer: the Southwest Oncology Group experience.
  19. J Clin Oncol 1991; 9: 1618–1626.
  20. Borges, M., Sculier, JP., Paesmans, M., et al. Prognostic
  21. factors for response to chemotherapy containing
  22. platinum derivatives in patients with unresectable nonsmall
  23. cell lung cancer (NSCLC). Lung Cancer 1996;16:
  24. Stanley, KE. Prognostic factors for survival in patients
  25. with inoperable lung cancer. J Natl Cancer Inst;65:25–32.
  26. Hillner BE, McDonald MK, Desch CE, Smith TJ,
  27. Penberthy L, Retchin SM. A comparison of patterns of
  28. care of nonsmall cell lung carcinoma patients in a
  29. younger and Medigap commercially insured cohort.
  30. Cancer 1998;83: 1930–1937.
  31. Smith TJ, Penberthy L, Desch CE, et al. Differences in
  32. initial treatment patterns and outcomes of lung cancer in
  33. the elderly. Lung Cancer 1995;13:235–252.
  34. Jeremic B, Shibamoto Y. Pre-treatment prognostic
  35. factors in patients with stage III non-small cell lung
  36. cancer treated with hyperfractionated radiation therapy
  37. with or without concurrent chemotherapy. Lung Cancer; 13: 21–30.
  38. Langer C, Hsu C, Curran D, et al. Do elderly patients
  39. with locally advanced non-small cell lung cancer benefit
  40. from combined modality therapy? A secondary analysis
  41. of RTOG 94-10. Int J Radiat Oncol Biol Phys 2001; 51:
  42. Gauden SJ, Tripcony L. The curative treatment by
  43. radiation therapy alone of Stage I non- small cell lung
  44. cancer in a geriatric population. Lung Cancer 2001; 32:
  45. Sause W, Kolesar P, Taylor SI, et al. Final results of
  46. phase III trial in regionally advanced unresectable nonsmall
  47. cell lung cancer: Radiation Therapy Oncology
  48. Group, Eastern Cooperative Oncology Group, and
  49. Southwest Oncology Group. Chest 2000; 117: 358–364.
  50. Newman AB, Yanez D, Harris T, et al. Weight change
  51. in old age and its association with mortality. J Am
  52. Geriatr Soc 2001; 49: 1309–1318.
  53. Movsas B, Scott C, Sause W, et al. The benefit of
  54. treatment intensification is age and histology-dependent
  55. in patients with locally advanced non-small cell lung
  56. cancer (NSCLC): a quality-adjusted survival analysis of
  57. radiation therapy oncology group (RTOG)
  58. chemoradiation studies. Int J Radiat Oncol Biol Phys; 45: 1143–1149.
  59. Numico G, Russi E, Merlano M. Best supportive care in
  60. non-small cell lung cancer: Is there a role for
  61. radiotherapy and chemotherapy? Lung Cancer 2001; 32:
  62. Chemotherapy in non-small cell lung cancer: a metaanalysis
  63. using updated data on individual patients from
  64. randomized clinical trials. Non-small Cell Lung
  65. Cancer Collaborative Group. BMJ 1995; 311: 899–909.
  66. Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of
  67. chemotherapy for advanced lung cancer in the elderly:
  68. instrumental variable and propensity analysis. J Clin
  69. Oncol 2001; 19: 1064–1070.
  70. Effects of vinorelbine on quality of life and survival of
  71. elderly patients with advanced non-small cell lung
  72. cancer. The Elderly Lung Cancer Vinorelbine Italian
  73. Study Group. J Natl Cancer Inst 1999; 91: 66–72.
  74. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for
  75. cancer: the Multicenter Italian Lung Cancer in the
  76. Elderly Study (MILES) phase III randomized trial. J
  77. Natl Cancer Inst 2003, 95: 362–372.
  78. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus
  79. vinorelbine versus vinorelbine alone in elderly patients
  80. with advanced non-small cell lung cancer. J Clin Oncol; 18: 2529–2536.
  81. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based
  82. therapy for elderly patients with advanced non-small cell
  83. lung cancer: implications of Eastern Cooperative
  84. Oncology Group 5592, a randomized trial. J Natl Cancer
  85. Inst 2002; 94: 173–181.
  86. Kelly K, Giarritta S, Akerley W, et al. Should older
  87. patients (Pts) receive combination chemotherapy for
  88. advanced stage non-small cell lung cancer (NSCLC)?
  89. An analysis of Southwest Oncology Trials 9509 and
  90. Proc Am Soc Clin Oncol 2001; 20: 329a.
  91. Hensing TA, Socinski MA, Schell MJ, et al. Age does
  92. not alter toxicity or survival for patients (pts) with stage
  93. IIIB/IV non-small cell lung cancer (NSCLC) treated
  94. with carboplatin (C) and paclitaxel (P). Proc Am Soc
  95. Clin Oncol 2001; 20: 346a.
  96. Lilenbaum RC, Herndon J, List M, et al. Single-agent
  97. (SA) versus combination chemotherapy (CC) in
  98. advanced non-small cell lung cancer (NSCLC): a
  99. CALGB randomized trial of efficacy, quality of life
  100. (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol; 21: 1a.
  101. Marmara Medical Journal 2008;21(1);011-020
  102. Görkem Aksu, et al.
  103. Radiotherapy as the primary and palliative treatment for patients aged 75 or over with locally advanced and metastatic
  104. Non-Small Cell Lung Cancer: Analysis of 45 cases with a review of the literature
  105. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of
  106. ZD1839 (‘Iressa’) in advanced non-small cell lung
  107. cancer (NSCLC) patients who had failed platinum- and
  108. docetaxel-based regimens (IDEAL 2). Proc Am Soc
  109. Clin Oncol 2002; 21: 292a
  110. Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional
  111. randomized phase II trial of gefitinib for
  112. previously treated patients with advanced non-small cell
  113. lung cancer. J Clin Oncol 2003; 21: 2237–2246.